Harrow (HROW) Depreciation & Amortization (CF) (2010 - 2026)
Harrow (HROW) posted quarterly Depreciation & Amortization (CF) of $455000.0 for Q1 2026, down 2.15% year-over-year from $465000.0 in Q1 2025, and down 1.94% quarter-over-quarter from $464000.0 in Q4 2025.
Harrow (HROW) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Harrow's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $455000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 2.15% year-over-year to $455000.0; the TTM figure through Mar 2026 stood at $1.9 million (up 1.17% YoY), while the FY2025 annual figure was $1.9 million, up 3.51% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $455000.0, down from $464000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $497000.0 in Q3 2024, with the low at $247000.0 in Q3 2022.
- The 5-year median for Depreciation & Amortization (CF) is $435000.0 (2023), against an average of $425117.6.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) sank 38.1% in 2022, then surged 63.97% in 2023.
- Harrow's Depreciation & Amortization (CF) stood at $387000.0 in 2022, then advanced by 12.4% to $435000.0 in 2023, then rose by 7.59% to $468000.0 in 2024, then declined by 0.85% to $464000.0 in 2025, then decreased by 1.94% to $455000.0 in 2026.
- Business Quant data shows HROW's Depreciation & Amortization (CF) at $455000.0 in Q1 2026, $464000.0 in Q4 2025, and $490000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Harrow | 1.53 Bn | 1.45 Bn | 50.36 Mn | 460,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 460,000.00 |
| Jun 30, 2026 | 460,000.00 |
| Mar 31, 2026 | 455,000.00 |
| Mar 31, 2026 | 455,000.00 |
| Dec 31, 2025 | 464,000.00 |
| Dec 31, 2025 | 464,000.00 |
| Sep 30, 2025 | 490,000.00 |
| Sep 30, 2025 | 490,000.00 |
| Jun 30, 2025 | 496,000.00 |
| Jun 30, 2025 | 496,000.00 |
| Mar 31, 2025 | 465,000.00 |
| Mar 31, 2025 | 465,000.00 |
| Dec 31, 2024 | 468,000.00 |
| Dec 31, 2024 | 468,000.00 |
| Sep 30, 2024 | 497,000.00 |
| Sep 30, 2024 | 497,000.00 |
| Jun 30, 2024 | 453,000.00 |
| Jun 30, 2024 | 453,000.00 |
| Mar 31, 2024 | 432,000.00 |
| Mar 31, 2024 | 432,000.00 |